摘要
目的探讨二仙汤治疗男性更年期综合征临床疗效的个体差异与细胞色素P450 1A2(CYP1A2)酶基因单核苷酸多态性的相关性。方法48例肾阴阳两虚证男性更年期综合征患者使用二仙汤治疗3个月,采用伊斯坦布尔Bosphorus大学心理系症状量化评分法并参考《中药新药临床研究指导原则》,对肾阴阳两虚证量化评分,用聚合酶链反应(PCR)扩增CYP1A2 G2964A基因,分析二仙汤的临床疗效与CYP1A2 G2964A酶基因单核苷酸多态性的关系。结果治疗组与正常对照组之间基因型及等位基因分布无显著性差异,有效组32例受试者中有16例的CYP1A2 G2964A基因型为G/G(56.25%),无效组16例受试者中有11例的CYP1A2 G2964A基因型为G/A(68.75%)。基因组间治疗前、治疗后的症状、体征评分无明显差异;基因组间肾阴阳两虚证主证、次症评分也无明显差异。结论二仙汤治疗男性更年期综合征个体含CYP1A2 G2964A基因型为G/G有效率较高,个体含CYP1A2 G2964A基因型为G/A无效率较高。
Objective To investigate the genetic association between mutation in cytochrome P450 1A2 （CYP1A2） gene and Erxian suop response. Methods Forty-eight patients with male climacteric syndrome of both Yin and Yang deficiency received a treatment of erxian suop with three months. The severity of symptoms and responses to Erxian suop were quantizated by the method of Department of Psychology in Istanbul Bosphorus University and Clinical Research Guidance Principle on New Drug of Traditional Chinese Medicine published by China. A single nucleotide polymorphism （SNP） at position 2964 （G-A） of CYP1A2 gene were identified by polymerase chain reaction （PCR） in order to analyse the relationship between Erxian response and CYP1A2 single nucleotide polymorphism. Results Statistical analysis showed there was no significant difference among genetype and genetype distribution of CYP1A2 G2964A between the patients and control group. The genotype of the 16 patients among 32 effective patients was G/G （56.25%）. The genotype of the 11 patients among 16 ineffective patients was G/A （68.75%）. There was no significant difference in symptoms, physical sign between the two groups at the pre-treat and post-treat. Also the two groups had no significant difference among the score of major symptoms and hyposymptoms. Conclusion The patients with genotype of G/G have higher efficiency, while with genotype of G/A have lower efficiency among patients with CYP1A2 G2964A gene when treated with erxian soup.
出处
《中国中医药信息杂志》
CAS
CSCD
2008年第7期12-14,共3页
Chinese Journal of Information on Traditional Chinese Medicine
基金
广东省中医药管理局课题(1060083)
广东省自然科学基金(7004840)
